Payment overview · 2025
General Payments
$79.87
4 reported records · 2 companies
Healthcare provider profile · identity verified
Mark Edward Holowinski, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SAINT CLAIR SHORES, MI · NPI 1023010063
Verified facts
What the public records show
CMS Open Payments records show Mark Edward Holowinski, M.D. received $79.87 in general payments during 2025 across 4 reported records.
Exact Sciences Corporation accounted for 76.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $61.14 | 76.5% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.73 | 23.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $79.87 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $61.14 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 58 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 356 | 86 |
| Atorvastatin Calcium | Atorvastatin Calcium | 311 | 88 |
| Lisinopril | Lisinopril | 306 | 82 |
| Amlodipine Besylate | Amlodipine Besylate | 261 | 71 |
| Metformin Hcl | Metformin Hcl | 234 | 67 |
| Omeprazole | Omeprazole | 210 | 63 |
| Simvastatin | Simvastatin | 181 | 45 |
| Fluticasone Propionate | Fluticasone Propionate | 161 | 67 |
| Meloxicam | Meloxicam | 148 | 42 |
| Topiramate | Topiramate | 146 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 142 | 52 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 139 | 40 |
| Alprazolam | Alprazolam | 132 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 128 | 37 |
| Gabapentin | Gabapentin | 125 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 124 | 43 |
| Losartan Potassium | Losartan Potassium | 119 | 36 |
| Famotidine | Famotidine | 117 | 38 |
| Furosemide | Furosemide | 115 | 33 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 112 | 34 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 109 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 106 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 94 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 92 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 88 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 86 | 27 |
| Trazodone Hcl | Trazodone Hcl | 81 | 17 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 77 | suppressed |
| Prednisone | Prednisone | 77 | 56 |
| Allopurinol | Allopurinol | 71 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 70 | 22 |
| Januvia | Sitagliptin Phosphate | 69 | 13 |
| Eliquis | Apixaban | 67 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 66 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 19 |
| Montelukast Sodium | Montelukast Sodium | 65 | 27 |
| Glimepiride | Glimepiride | 63 | 16 |
| Tramadol Hcl | Tramadol Hcl | 63 | 15 |
| Ozempic | Semaglutide | 58 | suppressed |
| Amoxicillin | Amoxicillin | 56 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 56 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 55 | 16 |
| Azelastine Hcl | Azelastine Hcl | 54 | 19 |
| Carvedilol | Carvedilol | 53 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 53 | 18 |
| Jardiance | Empagliflozin | 53 | 12 |
| Potassium Chloride | Potassium Chloride | 53 | 19 |
| Cephalexin | Cephalexin | 50 | 33 |
| Glipizide Er | Glipizide | 50 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 45 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 42 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | suppressed |
| Atenolol | Atenolol | 38 | 12 |
| Sertraline Hcl | Sertraline Hcl | 38 | 13 |
| Valacyclovir | Valacyclovir Hcl | 38 | 17 |
| Ibuprofen | Ibuprofen | 37 | 15 |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Lidocaine | Lidocaine | 29 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 25 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 16 |
| Eszopiclone | Eszopiclone | 24 | suppressed |
| Fluconazole | Fluconazole | 24 | 13 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 24 | 16 |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 19 |
| Azithromycin | Azithromycin | 21 | 19 |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Ciclopirox | Ciclopirox | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 20 |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | 12 |
| Naproxen | Naproxen | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 17 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Nystop | Nystatin | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Metaxalone | Metaxalone | 14 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 14 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $79.87 · 4 records | Exact Sciences Corporation | Cologuard Collection Kit, Ozempic, Rybelsus | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error